Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Authors: Lugui Qiu[1,2], Jennifer R. Brown[3], Barbara Eichhorst[4], Nicole Lamanna[5], Susan M. O'Brien[6], Constantine S. Tam[7], Maciej Kaźmierczak[8], Wojciech Jurczak[9], Keshu Zhou[10], Martin Simkovic[11], Jiri Mayer[12], Amanda Gillespie-Twardy[13], Alessandra Ferrajoli[14], Peter S. Ganly[15], Robert Weinkove[16,17], Sebastian Grosicki[18], Andrzej Mital[19], Tadeusz Robak[20], Anders Osterborg[21,22], Habte A. Yimer[23], Megan (Der Yu) Wang[24], Tommi Salmi[25], Liping Wang[26], Jessica Li[24], Kenneth Wu[24], Aileen Cohen[24], Mazyar Shadman[27,28]

Affiliations: [1]National Clinical Research Center for Hematological Disorders, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; [2]Tianjin Institutes of Health Science, Tianjin, China; [3]Dana-Farber Cancer Institute, Boston, MA, USA; [4]University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany; [5]Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; [6]University of California, Irvine, CA, USA; [7]Alfred Hospital and Monash University, Melbourne, VIC, Australia; [8]Poznan University of Medical Sciences, Poznan, Poland; [9]Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland; [10]Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; [11]4th Department of Internal Medicine-Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czech Republic ; [12]Masaryk University and University Hospital, Brno, Czech Republic; [13]Blue Ridge Cancer Care, Roanoke, VA, USA; [14]The University of Texas MD Anderson Cancer Center, Houston, TX, USA; [15]Christchurch Hospital, Christchurch, New Zealand; [16]Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast & Hutt Valley, Wellington, New Zealand; [17]Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand; [18]Medical University of Silesia, Katowice, Poland; [19]Medical University of Gdańsk, Gdańsk, Poland; [20]Medical University of Lodz, Lodz, Poland; [21]Karolinska Institutet, Stockholm, Sweden; [22]Karolinska University Hospital, Stockholm, Sweden; [23]Texas Oncology-Tyler/US Oncology Research, Tyler, TX, USA; [24]BeiGene USA, Inc, San Mateo, CA, USA; [25]BeiGene International GmbH, Basel, Switzerland; [26]BeiGene (Beijing) Co., Ltd., Beijing, China; [27]Fred Hutchinson Cancer Center, Seattle, WA, USA; [28]Department of Medicine, University of Washington, Seattle, WA, USA

ABSTRACT

Objective: In the randomized, phase 3 ALPINE study (NCT03734016), zanubrutinib demonstrated superior progression-free survival (PFS) and overall response rate (ORR) over ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) (Brown et al. NEJM; 2022). Here, we report updated results after more than 3 years of follow-up.

Methods: Patients with R/R CLL/SLL, ≥1 prior therapy, and measurable disease were randomized 1:1 to receive zanubrutinib or ibrutinib. Efficacy was evaluated by the investigator based on 2008 iwCLL criteria; sensitivity analyses were conducted to confirm PFS results. Updated safety analyses were performed. All reported P-values are descriptive.

Results: As of 15-September-2023, 652 patients received zanubrutinib (n=327) or ibrutinib (n=325); 194 (59%) remain on zanubrutinib and 152 (47%) on ibrutinib. 130 zanubrutinib-treated and 172 ibrutinib-treated patients discontinued treatment, most commonly due to AE (n=69, zanubrutinib; n=88,

ibrutinib) or disease progression (n=51, zanubrutinib; n=62, ibrutinib). At a median study follow-up of 39.0 months, PFS benefit of zanubrutinib was sustained over ibrutinib (HR: 0.68 [95% CI, 0.53-0.86]; P=.0011); 36-month PFS rates were 64.9% with zanubrutinib and 54.8% with ibrutinib. PFS benefits with zanubrutinib were observed in the del(17p)/TP53 subgroup (HR: 0.52 [95% CI, 0.33-0.83]; P=.0047); 36-month PFS rates were 58.6% and 41.3%, respectively. The zanubrutinib PFS benefit was confirmed in a sensitivity analysis that included only progression and death events occurring on active treatment (HR: 0.69 [95% CI, 0.50-0.95]; P=.0206). ORR was 85.6% and 74.8% (P=.0006), CR/CRi rates were 10.7% and 7.1%, and 90.2% and 82.8% achieved PR-L or better with zanubrutinib and ibrutinib, respectively. 64 (19.6%) patients treated with zanubrutinib and 78 (24.0%) with ibrutinib had died (OS HR: 0.75 [95% CI, 0.54-1.05]); median OS was not reached. The most common any-grade AE with zanubrutinib and ibrutinib was COVID-19 (39.2% vs 27.2%). The most common grade ≥3 AE was neutropenia (both 17.3%). Overall cardiac events remained lower with zanubrutinib, including atrial fibrillation/flutter (6.8% vs 16.4%; P=.0001). No fatal cardiac events occurred with zanubrutinib, while 6 (1.9%) occurred with ibrutinib.

Conclusions: ALPINE was the first head-to-head comparison of BTK inhibitors to demonstrate PFS superiority. At median follow-up of 39 months, durable PFS benefits with zanubrutinib were observed across major subgroups, including sensitivity analyses. Safety/tolerability profiles were consistent with previous reports; cardiac safety profile remained favorable for zanubrutinib, with no new safety signals emerging with longer follow-up. These results reconfirm zanubrutinib has improved efficacy over ibrutinib and a more favorable safety profile in patients with R/R CLL/SLL.